REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
2. Jiang Z, Zeng G, Dai H, et al. Global, regional and national burden of liver cancer 1990-2021: a systematic analysis of the global burden of disease study 2021. BMC Public Health. 2025;25:931.
3. Chan SL, Sun HC, Xu Y, et al. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet. 2025;406:731-78.
4. Chen C, Xu Q, Wang T, et al. Comparative analysis of liver cancer burden trends in China and worldwide between 1990 and 2021. Front Public Health. 2025;13:1513210.
5. Qin Y, Tang C, Li J, Gong J. Liver cancer in China: the analysis of mortality and burden of disease trends from 2008 to 2021. BMC Cancer. 2024;24:594.
6. Zhang Y, Chen YX, Cao R, et al. Epidemiological characteristics and disease burden of liver cancer in Guangdong Province. Public Health Prev Med. 2026;37:68-72. (in Chinese). Available from http://fbyf.ijournals.cn/ggwsyyfyx/article/abstract/20260114 [accessed 5 November 2026].
7. Cao GW. Epidemiological characteristics and precision prevention and control of primary liver cancer in China. J Guangxi Med Univ. 2024;41:1455-63. (in Chinese).
8. He J, Chen WQ, Shen HB, et al. China guideline for liver cancer screening (2022, Beijing). J Clin Hepatol. 2022;38:1739-58. (in Chinese).
9. Lin D, Deng Z, Chen Z, et al. The disease burden and its distribution characteristics of clonorchiasis in Guangdong Province, Southern China. Parasit Vectors. 2024;17:353.
10. Hashem EM, Karrar AM, Mabrouk MS. Advancing liver cancer diagnosis and treatment with multi-omics approaches: a systematic review. Discov Oncol. 2025;16:2188.
11. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604.
12. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681-93.
13. Sato-Espinoza K, Valdivia-Herrera M, Chotiprasidhi P, Diaz-Ferrer J. Hepatocellular carcinoma in patients without cirrhosis. World J Gastroenterol. 2025;31:107100.
14. Li H, Wang J, Ming X, Zhou M, Zhou L. Comparison of machine learning and Cox regression models for prognostic analysis in hepatocellular carcinoma patients with distant metastasis. Surg Open Sci. 2025;27:36-44.
15. Chen J, Chen S, Li H, et al. Interpretable LASSO-Cox model: Hsp90α/albumin ratio predicts hepatocellular carcinoma prognosis. Transl Cancer Res. 2025;14:8462-74.
16. Fan H, Kouvari M, Guo C, et al. A comprehensive comparison of two commonly used BMI thresholds for non-communicable diseases and multimorbidity in the Chinese population. Clin Nutr. 2025;48:70-9.
17. Kaewdech A, Sripongpun P, Assawasuwannakit S, et al. FAIL-T (AFP, AST, tumor size, ALT, and tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE. Front Med. 2023;10:1077842.
18. National Health Commission of the People’s Republic of China. Reference intervals for common clinical immunological tests-Part 2: Serum alpha-fetoprotein, carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 15-3, carbohydrate antigen 125: WS/T 645.2-2018. Available from https://www.nhc.gov.cn/. [accessed 3 November 2026].
19. Zhou J, Sun H, Wang Z, et al. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition). Liver Cancer. 2025;14:779-835.
20. Cao W, Qin K, Liu B, Chen W. Cancer statistics in China: epidemiology, risk factors, and prevention. Chin J Cancer Res. 2025;37:912-28.
21. Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76:e70043.
22. Bai J, Zhou J, Zhao X, et al. Effect of AFP and PIVKA-II secretion status on prognosis of advanced hepatocellular carcinoma patients receiving TACE combined with systemic therapy. BMC Cancer. 2025;25:1701.
23. Wang Q, Liu F, Liu C, et al. Impact of body mass index in patients with hepatocellular carcinoma treated with TACE combined with lenvatinib and PD-1 inhibitors. Oncologie. 2025;27:603-14.
24. Ye Q, Yu Y, Pang S, et al. Nomogram for predicting postoperative recurrence in patients with microvascular invasion-negative hepatocellular carcinoma: development and validation. Front Immunol. 2025;16:1614392.
25. Fu J, Liu M, Chen S, Chen L, Liang S. Prognostic nomogram for hepatocellular carcinoma with major vascular invasion: a population-based study from the SEER database and a Chinese cohort. Eur J Med Res. 2025;30:836.
26. Chen QF, Lyu N, Wang X, et al. Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial. Int J Surg. 2023;109:3929-39.
27. Yuqin L, Hongyan L, Hongyuan L, et al. Lymph node metastasis in patients with hepatocellular carcinoma using machine learning: a population-based study. Front Oncol. 2025;15:1601985.
28. Ji K, Zhu H, Zhang C, et al. Nomogram-based prognostic stratification for patients with large hepatocellular carcinoma: a population study of SEER database and a Chinese cohort. J Gastrointest Oncol. 2024;15:2201-15.
29. Yao LQ, Fan HX, Chen FJ, et al. Heterogeneity in prognosis for early-stage hepatocellular carcinoma after hepatectomy: a multicenter analysis of 4,623 patients across five major staging systems. Eur J Surg Oncol. 2025;51:110383.
30. Suddle A, Reeves H, Hubner R, et al. British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults. Gut. 2024;73:1235-68.
31. Park MS, Cho JY, Kim E, et al. Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association. J Liver Cancer. 2025;25:140-59.
32. Di Sandro S, Centonze L, Ratti F, et al. ; IGoMILS Collaborative Group. Robotic vs laparoscopic resection for hepatocellular carcinoma: multicentric propensity-score matched analysis of surgical and oncologic outcomes in 647 patients. Updates Surg. 2025;77:1451-62.
33. Riescher-Tuczkiewicz A, Caldwell SH, Kamath PS, Villa E, Rautou PE; Bleeding in liver diseases investigators†, Bleeding in liver diseases investigators. Expert opinion on bleeding risk from invasive procedures in cirrhosis. JHEP Rep. 2024;6:100986.
34. Madan K, Kumar A. To biopsy or not to biopsy? Re-examining the role of tissue diagnosis in hepatocellular carcinoma. J Clin Exp Hepatol. 2026;16:103209.
35. Lu J, Wang F, Zhang W, et al. Perioperative changes in serum transaminases levels predicts long-term survival following liver resection of hepatocellular carcinoma. Ann Surg Oncol. 2025;32:2446-55.
36. Zheng Z, Mei J, Guan R, et al. A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy. Cancer Immunol Immunother. 2024;73:158.
37. Kostakis ID, Kotelis N, Safavi D, Iype S. Preoperative blood tests provide diagnostic and prognostic information about patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2025;37:219-29.
38. Crișan D, Procopeț B, Crăciun R, et al. The role of easy-to-use non-invasive scores in the assessment of hepatocellular carcinoma prognosis - data from the romanian hepatocellular carcinoma registry. J Gastrointestin Liver Dis. 2025;34:205-13.
39. Gao B, Lu Y, Lai X, et al. Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications. Front Immunol. 2025;16:1592837.
40. Huo RR, Pan LX, Wu PS, et al. Prognostic value of aspartate aminotransferase/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy. BJS Open. 2024;8:zrad155.
41. Mo Q, Liu Y, Zhou Z, et al. Prognostic value of aspartate transaminase/alanine transaminase ratio in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy. Front Oncol. 2022;12:876900.
42. Ikuta S, Aihara T, Nakajima T, Yamanaka N. Alpha-fetoprotein as a prognostic factor in alpha-fetoprotein-negative hepatocellular carcinoma - integration into post-resection prognostic nomograms. Contemp Oncol. 2025;29:69-76.
43. Xu S, Duan L, Cho WC, Jin S, Ma L. Identification of patients with early-stage hepatocellular carcinoma benefiting from neoadjuvant chemotherapy-A SEER-based study. J Gastrointest Cancer. 2025;56:144.
44. Yao LQ, Fan ZQ, Wang MD, et al. Prognostic value of serum α-fetoprotein level as an important characteristic of tumor biology for patients undergoing liver resection of early-stage hepatocellular carcinoma (BCLC Stage 0/A): a large multicenter analysis. Ann Surg Oncol. 2024;31:1219-31.
45. Glowska-Ciemny J, Pankiewicz J, Malewski Z, von Kaisenberg C, Kocylowski R. Alpha-fetoprotein (AFP) - new aspects of a well-known marker in perinatology. Ginekol Pol. 2022;93:70-5.
46. Luo P, Wu S, Yu Y, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res. 2020;26:599-603.
47. Jeng KS, Chang CF, Sheen IS, Jeng CJ, Wang CH. Cellular and molecular biology of cancer stem cells of hepatocellular carcinoma. Int J Mol Sci. 2023;24:1417.
48. Ashokachakkaravarthy K, Pottakkat B. Mitotic quiescence in hepatic cancer stem cells: An incognito mode. Oncol Rev. 2020;14:452.
49. Xu Y, Guo Q, Wei L. The emerging influences of alpha-fetoprotein in the tumorigenesis and progression of hepatocellular carcinoma. Cancers. 2021;13:5096.
50. Gramantieri L, Giovannini C, Suzzi F, Leoni I, Fornari F. Hepatic cancer stem cells: molecular mechanisms, therapeutic implications, and circulating biomarkers. Cancers. 2021;13:4550.
51. Zhu M, Li W, Lu Y, et al. HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway. Int J Cancer. 2017;140:1346-55.
52. Munson PV, Adamik J, Butterfield LH. Immunomodulatory impact of α-fetoprotein. Trends Immunol. 2022;43:438-48.
53. Kim HI, Lim J, Shim JH. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2022;148:2069-77.
54. Huang DQ, Hoang JK, Kamal R, et al. Antiviral therapy utilization and 10-year outcomes in resected hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma. J Clin Oncol. 2024;42:790-9.
55. Liu J, Bai S, Shi X, et al. Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: a ten-year retrospective cohort study. Eur J Surg Oncol. 2025;51:109621.
56. Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77:128-39.
57. Liang Y, Zhong D, Zhang Z, et al. Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma. BMC Cancer. 2024;24:291.
58. Mauro E, de Castro T, Zeitlhoefler M, et al. Hepatocellular carcinoma: epidemiology, diagnosis and treatment. JHEP Rep. 2025;7:101571.
59. Xie H, Shi B, Fan J, et al. A predictive model based on radiomics, clinical features, and pathologic indicators for disease-free survival after liver transplantation for hepatocellular carcinoma: a 7-year retrospective study. J Gastrointest Oncol. 2024;15:2187-200.
60. Wu Y, Wu J, Duan S, et al. A refined prognostic model for postoperative overall survival in hepatocellular carcinoma based on CODEX-based multiproteomics and radiomics. J Hepatocell Carcinoma. 2025;12:2169-82.
61. Bissonnette J, Riescher-Tuczkiewicz A, Gigante E, et al. Predicting bleeding after liver biopsy using comprehensive clinical and laboratory investigations: a prospective analysis of 302 procedures. J Thromb Haemost. 2022;20:2786-96.
